Activation of ERK5 in angiotensin II-induced hypertrophy of human aortic smooth muscle cells

Molecular and Cellular Biochemistry

Volumn 322, Issue 1-2, 2009, Pages 171-178

  Zhao, Zhuo ^a,c   Geng, Jing ^a   Ge, Zhiming ^a   Wang, Wei ^b   Zhang, Yun ^a   Kang, Weiqiang ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^c JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Angiotensin II; ERK5; Humanaortic smooth muscle cells; Hypertrophy

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; BETA ACTIN; MITOGEN ACTIVATED PROTEIN KINASE 7; MYOCYTE ENHANCER FACTOR 2; SMALL INTERFERING RNA; VALSARTAN;

AORTA MEDIA; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; ENZYME ACTIVITY; GENE SILENCING; GENE TARGETING; HEART HYPERTROPHY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; TRANSCRIPTION INITIATION;

ANGIOTENSIN II; AORTA; CELL ENLARGEMENT; CELLS, CULTURED; ENZYME ACTIVATION; HUMANS; MADS DOMAIN PROTEINS; MITOGEN-ACTIVATED PROTEIN KINASE 7; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; MYOGENIC REGULATORY FACTORS; PHOSPHORYLATION;

EID: 59349104358     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-008-9954-7     Document Type: Article

References (42)

1. Abe J, Kusuhara M, Ulevitch RJ et al (1996) Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem 271:16586-16590. doi: 10.1074/jbc.271.28.16586
2. Zhou G, Bao ZQ, Dixon JE (1995) Components of a new human protein kinase signal transduction pathway. J Biol Chem 270:12665-12669
3. Yan C, Luo H, Lee JD et al (2001) Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains. J Biol Chem 276:10870-10878. doi: 10.1074/jbc.M009286200
4. Wang X, Merritt AJ, Seyfried J et al (2005) Targeted deletion of mek5 causes early embryonic death and defects in the extracellular signal-regulated kinase 5/myocyte enhancer factor 2 cell survival pathway. Mol Cell Biol 25:336-345. doi: 10.1128/MCB.25.1.336-345.2005
5. Regan CP, Li W, Boucher DM et al (2002) Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci USA 99:9248-9253. doi: 10.1073/pnas.142293999
6. Sohn SJ, Sarvis BK, Cado D et al (2002) ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 277:43344-43351. doi: 10.1074/jbc.M207573200
7. Yan L, Carr J, Ashby PR, Murry-Tait V et al (2003) Knockout of ERK5 causes multiple defects in placental and embryonic development. BMC Dev Biol 3:11. doi: 10.1186/1471-213X-3-11
8. Wang X, Tournier C (2006) Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal 18:753-760. doi: 10.1016/ j.cellsig.2005.11.003
9. Rovida E, Navari N, Caligiuri A et al (2008) ERK5 differentially regulates PDGF-induced proliferation and migration of hepatic stellate cells. J Hepatol 48:107-115. doi: 10.1016/j.jhep.2007.08.010
10. Sharma G, Goalstone ML (2007) Regulation of ERK5 by insulin and angiotensin-II in vascular smooth muscle cells. Biochem Biophys Res Commun 354:1078-1083. doi: 10.1016/j.bbrc.2007.01.102
11. Mulloy R, Salinas S, Philips A et al (2003) Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22:5387-5398. doi: 10.1038/ sj.onc.1206839
12. Dong F, Gutkind JS, Larner AC (2001) Granulocyte colony-stimulating factor induces ERK5 activation, which is differentially regulated by protein-tyrosine kinases and protein kinase C. Regulation of cell proliferation and survival. J Biol Chem 276:10811-10816. doi: 10.1074/ jbc.M008748200
13. Kato Y, Tapping RI, Huang S et al (1998) Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395:713-716. doi: 10.1038/27234
14. Dinev D, Jordan BW, Neufeld B et al (2001) Extracellular signal regulated kinase 5 (ERK5) is required for the differentiation of muscle cells. EMBO Rep 2:829-834. doi: 10.1093/embo-reports/kve177
15. Zhao M, Liu Y, Bao M et al (2002) Vascular smooth muscle cell proliferation requires both p38 and BMK1 MAP kinases. Arch Biochem Biophys 400:199-207. doi: 10.1016/S0003-9861(02)00028-0
16. Kato Y, Kravchenko VV, Tapping RI et al (1997) BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J 16:7054-7066. doi: 10.1093/emboj/16.23.7054
17. Diaz-Meco MT, Moscat J (2001) MEK5, a new target of the atypical protein kinase C isoforms in mitogenic signaling. Mol Cell Biol 21:1218-1227. doi: 10.1128/MCB.21.4.1218-1227.2001
18. Dzau VJ, Lopez-Ilasaca M (2005) Searching for transcriptional regulators of Ang II-induced vascular pathology. J Clin Invest 115:2319-2322. doi: 10.1172/JCI26384
19. Brasier AR, Jamaluddin M, Han Y et al (2000) Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol Cell Biochem 212:155-169. doi: 10.1023/A:1007133710837
20. Yoshida T, Hoofnagle MH, Owens GK (2004) Myocardin and Prx1 contribute to angiotensin II-induced expression of smooth muscle alpha-actin. Circ Res 94:1075-1082. doi: 10.1161/01.RES.0000125622.46280.95
21. Zhan Y, Brown C, Maynard E et al (2005) Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. J Clin Invest 115:2508-2516. doi: 10.1172/JCI24403
22. Takahashi Y, Watanabe H, Murakami M et al (2007) Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy. Atherosclerosis 195:287-296. doi: 10.1016/j.atherosclerosis.2006.12.033
23. Hou Y, Okamoto C, Okada K et al (2007) c-Myc is essential for urokinase plasminogen activator expression on hypoxia-induced vascular smooth muscle cells. Cardiovasc Res 75:186-194. doi: 10.1016/ j.cardiores.2007.02.033
24. Wong C, Jin ZG (2005) Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. J Biol Chem 280:33262-33269. doi: 10.1074/jbc.M503198200
25. Touyz RM, Berry C (2002) Recent advances in angiotensin II signaling. Braz J Med Biol Res 35:1001-1015. doi: 10.1590/S0100-879X2002000900001
26. Yoon SC, Ahn YM, Jun SJ et al (2005) Region-specific phosphorylation of ERK5-MEF2C in the rat frontal cortex and hippocampus after electroconvulsive shock. Prog Neuropsychopharmacol Biol Psychiatry 29:749-753. doi: 10.1016/j.pnpbp.2005.04.006
27. Shishido T, Woo CH, Ding B et al (2008) Effects of MEK5/ERK5 association on small ubiquitin-related modification of ERK5: Implications for diabetic ventricular dysfunction after myocardial infarction. Circ Res 102:1416-1425. doi: 10.1161/CIRCRESAHA.107.168138
28. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410:37-40. doi: 10.1038/35065000
29. Hayashi M, Kim SW, Imanaka-Yoshida K et al (2004) Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113:1138-1148
30. Cavanaugh JE, Ham J, Hetman M et al (2001) Differential regulation of mitogen-activated protein kinases ERK1/2 and ERK5 by neurotrophins, neuronal activity, and cAMP in neurons. J Neurosci 21:434-443
31. Fujii Y, Matsuda S, Takayama G et al (2008) ERK5 is involved in TCR-induced apoptosis through the modification of Nur77. Genes Cells 13:411-419. doi: 10.1111/j.1365-2443.2008.01177.x
32. Sharma G, Goalstone ML (2005) Dominant negative FTase (DNFTalpha) inhibits ERK5, MEF2C and CREB activation in adipogenesis. Mol Cell Endocrinol 245:93-104. doi: 10.1016/j.mce.2005.10.027
33. Ushio-Fukai M, Zuo L, Ikeda S et al (2005) CAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: Role in vascular hypertrophy. Circ Res 97:829-836. doi: 10.1161/01.RES.0000185322.46009.F5
34. Han J, Jiang Y, Li Z et al (1997) Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 386:296-299. doi: 10.1038/386296a0
35. Morimoto H, Kondoh K, Nishimoto S et al (2007) Activation of a C-terminal transcriptional activation domain of ERK5 by autophosphorylation. J Biol Chem 282:35449-35456. doi: 10.1074/ jbc.M704079200
36. Mody N, Leitch J, Armstrong C et al (2001) Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 502:21-24. doi: 10.1016/ S0014-5793(01)02651-5
37. Nishimoto S, Nishida E (2006) MAPK signalling: ERK5 versus ERK1/2. EMBO Rep 7:782-786. doi: 10.1038/sj.embor.7400755
38. Benedetto BD, Hitz C, Hölter SM et al (2007) Differential mRNA distribution of components of the ERK/MAPK signalling cascade in the adult mouse brain. J Comp Neurol 500:542-556. doi: 10.1002/cne.21186
39. Chen HI, Hsieh NK, Chang HR et al (2008) Arterial haemodynamics on ventricular hypertrophy in rats with simulated aortic stiffness. Pflugers Arch 455:595-606. doi: 10.1007/s00424-007-0320-5
40. Daugherty A, Cassis L (2004) Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14:117-120. doi: 10.1016/ j.tcm.2004.01.002
41. Takahashi N, Saito Y, Kuwahara K et al (2005) Hypertrophic responses to cardiotrophin-1 are not mediated by STAT3, but via a MEK5-ERK5 pathway in cultured cardiomyocytes. J Mol Cell Cardiol 38:185-192. doi: 10.1016/ j.yjmcc.2004.10.016
42. Shin SY, Yang JM, Choo SM et al (2008) System-level investigation into the regulatory mechanism of the calcineurin/NFAT signaling pathway. Cell Signal 20:1117-1124. doi: 10.1016/j.cellsig.2008.01.023